II. Marine Natural Products
These are the compounds which are derived from marine organisms. There are different number of compounds that are derived from marine organisms by deep-sea collection and aquaculture technology.
• CYTARABINE (Isolated from Cryptothecacrypta) CYTARABINE is currently used in treatment of leukemia and lymphoma patients and important thing is that cytarabine is the first marine derived anticancer agent. Mechanism of action of Ecteinascidin is modification of DNA by guanine specific alkylation at N2 position.
• DOLASTATIN (Isolated from Dolabellaauricularia) Dolastatin 10 was selected for clinical trials. During clinical trials phase-1 and 2of Dolastatin-it was approved for solid tumour but no anticancer activity seen. Toxic effects are also observed by DolastatinLocal irritation at injection site and mild peripheral neuropathy.
It promotes the activity of protein kinase c but lacks the tumour promoting activity. It also has immunomodulatory effects. During clinical trials phase1 and 2 of Bryostatin-1, It shows antitumour activity in patients with malignant melanoma, lymphoma, ovarian carcinoma. And finally it shows no antitumour activity in patients of solid tumours and lung cancer during clinical trials phase1 and 2. It also stimulate some other biological activities which involve-immune system modulation, induction of cell differentiation, radioprotection, it also exert synergistic interaction with other anticancer agents such as Ara-C, Dolastatin, prednisone, Tamoxifen, Vincristine, Doxorubicin. Toxic effects are also observed by BryostatinMyalgia, local phlebitis, fatigue, nausea, vomiting and thrombocytopenia.
• DEPSIPEPTIDE (Isolated from Chromobacteriumviolaceum)
It shows cytotoxicity activity in various human solid tumour cell line. It act as inhibitor of a histone deacetylase. Clinical trials of Depsipeptide will begin soon. In UNITED STATES, we have 3 FDA approved marine derived drugs-• Cytarabine • Vidarabine • Ziconotide
• CYTARABINE (Isolated from Cryptothecacrypta) Cytarabine is also known as arabinosyl cytosine or Ara-C. Cytarabine is an S-phase specific antimetabolite cytotoxic agent and it convert cytosine arabinoside into cytosine arabinoside triphosphate and it compete with physiologic substrate deoxycitidine triphosphate and it results in inhibition of DNA polymerase and inhibition of DNA synthesis. Cytarabine currently available in 2 forms-
• Conventional Cytarabine • Liposomal formulations • Conventional Cytarabine is indicated for acute lymphocytic leukemia, acute myelocytic leukemia, meningeal leukemia.
• Liposomal Cytarabine is indicated for intrathecal treatment of lymphomatous meningitis.
• VIDARABINE (Isolated from Cryptothecacrypta)
Vidarabine also known as adenine arabinoside, Ara-A. Adenine arabinoside is converted into adenine arabinoside triphosphate which inhibit viral DNA polymerase and DNA synthesis of herpes, vaccinia. Marketing status of Vidarabine by USFDAConventional Vidarabine is used for treatment of acute keratoconjuctivitis, recurrent epithelial keratitis caused by herpes simplex virus type-1 &2.
• ZICONOTIDE (Isolated from venom of fish hunting marine snail conus magus).
Ziconotide is synthetic form of w-conotoxin. It was the first drug which is approved by USFDA. Trade name of ZICONOTIDE is Prialt. It has poor tissue penetration when it administered systemically. And also some hypotensive effects. So due to this it was administered by continous infusion by external or implanted pump. It shows good analgesic action with a novel mechanism of action. Ziconotide reversibly block Ntype calcium channel. In 2004, it received FDA approval for the treatment of chronic pain with cancer or AIDS.
• DISCODERMOLIDE (Isolated from Discodermia dissolute)
It was used as new immunosuppressive and also cytotoxin. In 1996, a discovery confirms that Discodermolide bound to microtubules more potently than Taxol.
Discodermolide induces G2/m phase cell cycle arrest in lymphoid and non-lymphoid cells. • KAHALALIDE F (Isolated from Elysiarufescens)
In 1990, it entered in preclinical testing but its mechanism of action had not fully determined. It is a broad spectrum growth inhibitory activity. It also shows high anticancer activity. After all over study of Aragusterol, investigators understood that it target the G1 phase of cell cycle by downregulatingcyclin dependent kinases and G1 cyclins and block the entry of human tumour cells into S-phase.
• ASCIDIDEMIN (Isolated from Cytodytesdellechiajei)
It was shown to be a potent inducer of apoptosis in both human and murine leukemia cells. It cause oxidative demage to DNA and it also exerts DNA cleaving activity.
AGENTS that are now withdrawn from antitumour clinical trials-

• DIDEMNIN B (Isolated from tunicate Trididemnum sodium)
In 2001, It shows good antitumour activity for both human tumour as well as in Athymic mice. But later, after all information of D idemin like treatment protocol And treatments of many cancer, the compound exerts too toxic and due to this, It was determind by NCI.
• GIROLLINE (Isolated from Pseudaxinyssacantharella) During clinical trial phase-1, Girolline was succeed in man but it shows hypertensive effects on treated patients so due to this trial were stopped.
• BENGAMIDE Bengamide A is used in this for clinical trial. This derivative shows inhibitor of methionine aminopeptidases and then it entered in clinical trial phase-1 in 2000 but it was withdrawn in middle of
• CRYPTOPHYCIN (isolated from a Lichen)
This compound shows only antifungal activity but it was too toxic also so thats why it was not procced. 
Future Prospects
The combination of new structural compounds with novel mechanism of action and translates into new methods to treat cancer and by which we can improve the results for patients. Marine natural compounds exerts as important sources of new drugs and lead structures. The aquaculture of source organisms including sponges, tunicates will supply new drug products and will progress in cancer applications.
